Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer

BackgroundA recent phase III clinical trial (NCT03981796) evaluated the efficacy and safety of dostarlimab combined with carboplatin-paclitaxel (DOS-CP) compared to placebo combined with carboplatin-paclitaxel (PLB-CP) as a first-line treatment for advanced endometrial cancer (EC). The NCT03981796 t...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Maojin You, Xiaoling Zeng, Jinrong Zhang, Yufan Huang, Yalan Zhang, Zhongjie Cai, Yingying Hu
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2023-09-01
Ráidu:	Frontiers in Immunology
Fáttát:	dostarlimab carboplatin-paclitaxel cost-effectiveness first-line treatment endometrial cancer
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1267322/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!